佳云科技 reported revenue of ¥0.47B for the period ended 2026-06-30, -58.4% year on year. Net income was ¥-0.01B, a -2.8% net margin on a 11.8% gross margin. The largest revenue line is 互联网营销业务 at 88% of the total. Free cash flow for the period was ¥0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.47B | -58.4% |
| Gross profit | ¥0.06B | — |
| Operating income | ¥-0.01B | — |
| Net income | ¥-0.01B | — |
| Gross margin | 11.8% | Net margin -2.8% |
| Revenue Q/Q | +15.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| 互联网营销业务 | ¥0.41B | 87.7% |
| 美妆护肤业务 | ¥0.06B | 12.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.41B | 88.2% |
| SG&A | ¥0.07B | 14.2% |
| Tax & other | ¥0.00B | 0.1% |
| Item | Amount |
|---|---|
| Total assets | ¥0.26B |
| Total liabilities | ¥0.11B |
| Shareholders' equity | ¥0.15B |
| Equity / assets | 56.5% |
| Operating cash flow | ¥0.01B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.01B |
| Cash conversion (OCF / net income) | 129% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
瑞丰高材 ・ 迪安诊断 ・ ST天玑 ・ 宝莱特 ・ 融捷健康 ・ 新开普 ・ 依米康 ・ 初灵信息 ・ 金信诺 ・ 卫宁健康 ・ 仟源医药 ・ 常山药业
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies